What is Corvus Pharmaceuticals?
Headquartered in Burlingame, California, Corvus Pharmaceuticals operates as a clinical-stage biopharmaceutical entity dedicated to the research, development, and commercialization of precisely targeted oncology therapies. The company distinguishes itself through a rigorous focus on high-unmet-need cancer markets, leveraging advanced scientific methodologies to create medicines that offer meaningful clinical benefits. By integrating deep expertise in immunology and oncology, Corvus maintains a robust market position, effectively bridging the gap between early-stage laboratory discovery and late-stage clinical validation. Its operational model is designed to navigate the high-risk, high-reward nature of drug development, positioning the firm as a critical player in the evolution of personalized cancer care.
How much funding has Corvus Pharmaceuticals raised?
Corvus Pharmaceuticals has raised a total of $244.3M across 4 funding rounds:
Series A
$33.5M
Series B
$75M
Stock Offering
$71M
Stock Offering
$64.8M
Series A (2014): $33.5M with participation from OrbiMed
Series B (2015): $75M led by OrbiMed, Sphera Funds Management, Novo Ventures, Cowen, venBio Select, Adams Street Partners, Rock Springs Capital, Blackrock, Cormorant Asset Management, Fidelity Management and Research Company, T. Rowe Price, Jennison Associates, and Roche
Stock Issuance/Offering (2016): $71M supported by Credit Suisse and Cowen & Co.
Stock Issuance/Offering (2018): $64.8M featuring Jefferies Financial Group and Credit Suisse
Key Investors in Corvus Pharmaceuticals
OrbiMed
OrbiMed is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health platforms to support innovation at various development stages.
Credit Suisse
Credit Suisse is a global financial services firm that provides investment banking and capital market solutions to support the growth and strategic objectives of life sciences companies.
Novo Ventures
Novo Ventures is the investment arm of the Novo Nordisk Foundation, focusing on long-term value creation within the global life sciences and biotechnology industries.
What's next for Corvus Pharmaceuticals?
With the infusion of capital from its recent strategic financing, Corvus Pharmaceuticals is well-positioned to accelerate its clinical trial milestones and expand its therapeutic portfolio. The company's forward-looking strategy centers on the maturation of its lead candidates, with a focus on achieving key data readouts that will validate its proprietary platform. As the firm continues to scale, management is expected to prioritize operational efficiency and potential collaborative partnerships to maximize the commercial viability of its pipeline. The ongoing support from institutional investors provides the necessary runway to navigate the regulatory complexities of the biopharmaceutical sector while maintaining a focus on long-term value creation for stakeholders in the oncology space.
See full Corvus Pharmaceuticals company page
